Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The view from managed care pharmacy

B R Luce1, C A Lyles, A M Rentz

  • 1MEDTAP International, Bethesda, MD, USA.

Health Affairs (Project Hope)
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The content validity of the PSS in patients with plaque psoriasis.

Journal of patient-reported outcomes·2018
Same author

Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries.

Current medical research and opinion·2010
Same author

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation.

Journal of medical economics·2009
Same author

Health and economic outcomes modeling practices: a suggested framework.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2005
Same author

Health-related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments.

Haemophilia : the official journal of the World Federation of Hemophilia·2004
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Managed care pharmacy directors prioritize clinical effectiveness in assessments. While open to industry partnerships for disease management, most support some Food and Drug Administration (FDA) regulation of pharmacoeconomic claims.

Area of Science:

  • Health Services Research
  • Pharmacy Administration
  • Health Economics

Background:

  • Managed care organizations (MCOs) play a crucial role in healthcare delivery and drug utilization.
  • Understanding the perspectives of MCO pharmacy directors is vital for navigating pharmaceutical market dynamics.
  • Pharmacoeconomics and disease management are increasingly important considerations for MCOs.

Purpose of the Study:

  • To survey managed care pharmacy directors on their views regarding pharmacoeconomics, disease management, and regulatory bodies.
  • To assess the perceived utility of different types of economic assessments in MCO decision-making.
  • To gauge MCOs' willingness to partner with pharmaceutical companies and their stance on FDA regulation of pharmacoeconomic claims.

Main Methods:

Related Experiment Videos

  • A stratified national telephone survey was conducted.
  • The survey included fifty-one managed care organizations.
  • Respondents were pharmacy directors within these organizations.

    • Main Results:

    • Clinical effectiveness assessments were rated as most useful, followed by cost-effectiveness, and then quality-of-life assessments.
    • Both peer-reviewed and industry literature were considered equally important for decision-making.
    • A majority of MCOs are open to or have existing partnerships with drug companies for disease management.
    • Seventy-six percent of MCOs support some FDA regulation of pharmacoeconomic claims, while 69% favor less stringent or no regulation compared to current standards.

    Conclusions:

    • Managed care pharmacy directors prioritize clinical effectiveness data in their evaluations.
    • MCOs show a willingness to collaborate with the pharmaceutical industry on disease management initiatives.
    • There is a divided opinion among MCOs regarding the level of FDA regulation for pharmacoeconomic claims, with a significant portion favoring less stringent oversight.